Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 or SHR-A2009 with antitumor therapy in unresectable or metastatic breast cancer (Ib/II)
CTR20233954Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Mar 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-8080, ruzaltatug rezetecan in breast cancer, sponsored by Shandong Sende. Started Mar 2024; status: active.
02
Drugs
HRS-8080ruzaltatug rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233954.